Junshi Biosciences

Rxilient Biotech and Junshi Biosciences form Joint Venture to Develop and Commercialize Toripalimab in Southeast Asia

Toripalimab is an anti-PD-1 monoclonal antibody independently developed by Junshi Biosciences. Junshi Biosciences has conducted over 30 clinical trials globally (in China, the USA, Southeast Asia, and Europe) covering more than 15 indications, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney, and skin.